About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Glaucoma Drug Added to Weight Loss Plan Helps Women With Blinding Disorder Linked to Obesity

by Thilaka Ravi on April 23, 2014 at 9:27 PM
Font : A-A+

Glaucoma Drug Added to Weight Loss Plan Helps Women With Blinding Disorder Linked to Obesity

An inexpensive glaucoma drug, when added to a weight loss plan, can improve vision for women with a disorder called idiopathic intracranial hypertension (IIH) reveals a study funded by the National Institutes of Health.

IIH, also called pseudotumor cerebri, predominantly affects overweight women of reproductive age. An estimated 100,000 Americans have it, and the number is rising with the obesity epidemic. The most common symptoms are headaches and visual problems, including blind spots, poor side vision, double vision and temporary episodes of blindness. About 5-10 percent of women with IIH experience disabling vision loss.

Advertisement

"Our results show that acetazolamide can help preserve and actually restore vision for women with IIH, when combined with a moderate but comprehensive dietary and lifestyle modification plan," said Michael Wall, M.D., a professor of neurology and ophthalmology at the University of Iowa in Iowa City.

The trial was funded by NIH's National Eye Institute, and coordinated by the Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC). The results were published today in the Journal of the American Medical Association, and will be presented on May 2 during the Clinical Trials plenary session of the American Academy of Neurology meeting in Philadelphia.
Advertisement

Acetazolamide (Diamox) is best known as a glaucoma drug. It has been commonly prescribed for IIH, but without much evidence that it helps. The IIH Treatment Trial tested the benefits of acetazolamide plus a weight loss plan versus the weight loss plan with a placebo pill, over six months. Patients in both treatment groups had improved vision, but those receiving the drug had the greatest improvement. All patients were allowed to take headache medications throughout the trial, and both groups experienced a similar reduction in headache.

"The vision problems associated with this condition can be extremely debilitating, at significant cost to patients and the health care system. Yet there are no established treatment guidelines. We made it a priority to develop an evidence-based treatment for helping patients keep their vision," said Eleanor Schron, Ph.D., director of clinical applications at NEI.

IIH is named for one of its key physical findings—an increased pressure within the fluid-filled spaces inside and around the brain. This in turn can cause swelling and damage to the optic nerves that connect the eyes to the brain. A 5-10 percent weight reduction appears to improve symptoms for many patients, but can be difficult to achieve and maintain. Acetazolamide is known to reduce fluid production in the brain, and is often used as an add-on therapy. In severe cases, surgical procedures may be used to relieve pressure on the optic nerve.

The dosing and results with acetazolamide vary. In high doses, the drug can produce side effects including fatigue, nausea, tingling hands and feet, and a metallic taste, usually triggered by carbonated drinks. British researchers completed a trial of the drug for IIH in 2011, but the results were inconclusive.

The NIH-funded trial involved 161 women and four men with IIH and mild vision loss, who were enrolled at 38 sites. At enrollment, their average body mass index (BMI) was about 40. A BMI of 30 or greater is considered obese. All participants were put on a weight loss plan to trim salt and about 500 to 1,000 calories from their food intake each day, with the goal to lose 6 percent of their starting weight. They were provided with a weight loss coach and some simple low-cost exercise equipment. This included a step counter and a resistance band, a piece of rubber tubing used for strength training. About half the participants were randomly assigned to receive acetazolamide. The drug was given at 1 gram daily for the first week and increased by a quarter gram each week, to reach the maximally tolerated dosage, or up to 4 grams daily. The other half of participants received a placebo in gradually increasing dosages.

After six months, both groups had improved scores on visual field tests, a measure of side or peripheral vision. Participants on acetazolamide improved by about twice as much as those on placebo. Compared to weight loss alone, the drug also helped reduce swelling of the optic nerve. The drug-weight loss combination also led to greater improvements in daily function and quality of life compared to weight loss alone, based on the NEI Visual Functioning Questionnaire.

In the placebo group, there were six treatment failures—defined as a substantial worsening of vision that required withdrawal from the trial. There was one treatment failure in the acetazolamide group.

Seven people on acetazolamide and one person on placebo stopped taking their assigned study medication because of perceived side effects. Three people on placebo were admitted to the hospital compared to six on the drug, two of whom developed kidney stones. All side effects were reversed by stopping the drug or reducing the dosage.

"This study provides a much-needed evidence base for using acetazolamide as an adjunct to weight loss for treating IIH," said Dr. Wall. "The drug has been around since the 1950s, and prior studies have found varying degrees of efficacy. One strength of our study is that we slowly introduced patients to the highest tolerated dose, in an attempt to maximize efficacy while limiting its side effects."

Another strength of the study was the weight loss program, he said. The New York Obesity Nutrition Research Center designed the program to achieve moderate, sustainable weight control with an emphasis on changing lifestyle, as opposed to just dieting.

The trial will follow participants for five years to gauge whether they're able to maintain a healthy weight and control their symptoms over the long term.

Dr. Wall serves as the trial director. NORDIC is chaired by Mark Kupersmith, M.D., who is director of neuro-ophthalmology services at the New York Eye and Ear Infirmary. The NORDIC data coordination and biostatistics center is directed by Karl Kieburtz, M.D., M.P.H., a professor of neurology and community and preventive medicine at the University of Rochester in New York, and by Michael McDermott, Ph.D., a professor of biostatistics and neurology, also at Rochester.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Guide to Brushing Your Teeth the Right Way
Resting Heart Rate
Is COVID-19 Vaccination during Pregnancy Safe?
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Bariatric Surgery Diet Pills Drug Toxicity Glaucoma Obesity The Cabbage Diet Zone Diet Mediterranean Diet Bulimia Nervosa The Macrobiotic Diet 

Recommended Reading
Obesity
Obesity is a condition where there is excess accumulation of body fat which poses a risk to the ......
Age Related Macular Degeneration
AGE RELATED MACULAR DEGENERATION (AMD) is a disease associated with ageing. It is a degenerative ......
How to Lose Weight?
Slide show which explains obesity causes and tips on how to lose weight. Exercising before ......
Quiz on Obesity
"We are indeed much more than what we eat, but what we eat can nevertheless help ......
Bulimia Nervosa
The term ''Bulimia'' refers to episodes of uncontrolled excessive eating, known as "binges," followe...
Diet Pills
Diet pills are flooding the market by millions. The positive side of diet pills to most people is th...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Glaucoma
Glaucoma is a group of disorders involving the optic nerve, often associated with a rise in intraocu...
Mediterranean Diet
Mediterranean diet has long been considered one of the healthiest diets on the planet. This diet pla...
The Cabbage Diet
The plausible reason that can be sited is the inherent low calorie property of ......
Zone Diet
The Zone Diet is a weight loss program with a ‘40:30:30’ plan for carbohydrates, fats and proteins ....

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use